Morphological and molecular basis of ovarian serous carcinoma

Serous carcinoma is the most common type of epithelial ovarian cancer. In this review, we provide a comprehensive picture of ovarian serous cancers from multiple aspects: the first part of this review summarizes the morphological, histological, and immunological signatures of ovarian serous carcinoma; subsequently, we review the history of the evolvement of different grading systems used in ovarian serous cancer; in the end, we focus on characterizing the genetics that underlie the 2-tiered pathways through which ovarian serous cancers are believed to arise: the low-grade and the high-grade pathways.

• Publication year

  2010

• Venue

  Journal of Biomedical Research

• Publication date

  2010-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1674-8301(10)60036-XPMID 23554638PMCID 3596590
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reference

  2008cited by this paper
• Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers

  2006cited by this paper
• Current issues in the pathology of ovarian cancer.

  2005cited by this paper
• Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis: A Mutational Analysis With Immunohistochemical Correlation

  2005cited by this paper
• Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer.

  2005cited by this paper
• World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs

  2005cited by this paper
• Origins and molecular pathology of ovarian cancer

  2005cited by this paper
• Ultrastructural study of benign, low-malignant potential (LMP), and malignant ovarian tumors

  2004cited by this paper
• Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

  2004cited by this paper
• A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes

  2004cited by this paper
• Cell cycle and apoptotic proteins in relation to ovarian epithelial morphology.

  2004cited by this paper
• Subclassification of Ovarian Surface Epithelial Tumors Based on Correlation of Histologic and Molecular Pathologic Data

  2004cited by this paper
• WT‐1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma

  2004cited by this paper
• Grading Ovarian Serous Carcinoma Using a Two-Tier System

  2004cited by this paper
• In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low‐grade serous tumours

  2004cited by this paper
• Blaustein’s Pathology of the Female Genital Tract

  2003cited by this paper
• BRAF mutation in papillary thyroid carcinoma.

  2003cited by this paper
• Prevention of ovarian cancer: intraepithelial neoplasia.

  2003cited by this paper
• Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.

  2003cited by this paper
• Pathology of ovarian carcinoma.

  2003cited by this paper
• Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.

  2003cited by this paper
• TP53 and ovarian cancer

  2003cited by this paper
• K-ras alterations in Danish ovarian tumour patients. From the Danish "Malova" Ovarian Cancer study.

  2003cited by this paper
• Prognostic Value of Histologic Grading of Ovarian Carcinomas

  2003cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• World Health Organization Classification of Tumours

  2002cited by this paper
• Inactivation of BRCA1 and BRCA2 in ovarian cancer.

  2002cited by this paper
• Inactivation of BRCA 1 and BRCA 2 in Ovarian Cancer

  2002cited by this paper
• Frequency of BRCA1 dysfunction in ovarian cancer.

  2002cited by this paper
• Cytogenetics and molecular genetics of ovarian cancer.

  2002cited by this paper
• Expression of cytokeratins 7 and 20 in ovarian neoplasia.

  2002cited by this paper
• Clinical Factors and Biomarkers Which Affect a New Universal Grading System for Ovarian Epithelial Carcinoma

  2001cited by this paper
• Tumor markers and molecular biological markers in gynecologic malignancies

  2001cited by this paper
• Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation

  2001cited by this paper
• Grading of Ovarian Carcinomas

  2000cited by this paper
• Histopathologic grading of ovarian carcinoma: a review and proposal.

  2000cited by this paper
• HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary.

  1999cited by this paper
• p53 mutations and expression in ovarian cancers: correlation with overall survival.

  1999cited by this paper
• Letter to the EditorTo the Editor

  1999cited by this paper
• The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer.

  1999cited by this paper
• Toward the development of a universal grading system for ovarian epithelial carcinoma.

  1999cited by this paper
• Toward the development of a universal grading system for ovarian epithelial carcinoma

  1998influential reference
• Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers.

  1998cited by this paper
• Quantitative prognostic features in FIGO I ovarian cancer patients without postoperative treatment.

  1998cited by this paper
• Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

  1998cited by this paper
• Expression of E‐cadherin, α‐catenin and β‐catenin in normal ovarian surface epithelium and epithelial ovarian cancers

  1998cited by this paper
• BRCA1 is a component of the RNA polymerase II holoenzyme.

  1997cited by this paper
• K‐ras mutations in mucinous ovarian tumors

  1997cited by this paper
• EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients.

  1997cited by this paper
• Genetic analysis of benign, low-grade, and high-grade ovarian tumors.

  1995cited by this paper
• The genetics of breast and ovarian cancer.

  1995cited by this paper
• BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT

  1995cited by this paper
• Further evaluation of reproducibility and prognostic value of histologic typing and grading in FIGO stage I ovarian cancer patients without systemic locoregional adjuvant treatment

  1994cited by this paper
• Can we predict a high risk group in stage I epithelial ovarian cancer?

  1992cited by this paper
• Reproducibility and prognostic value of histologic type and grade in early epithelial ovarian cancer

  1992cited by this paper
• A new histologic grading index in ovarian carcinoma.

  1989cited by this paper
• International Agency for Research on Cancer.

  1985influential reference
• Studies on Bilirubin in Amniotic Fluid: With Special Reference to Liver Function Tests

  1971cited by this paper
• Classification and staging of malignant tumours in the female pelvis.

  1968cited by this paper

• Iatrogenic Leptomeningeal Carcinomatosis Following Craniotomy for Resection of Metastatic Serous Ovarian Carcinoma: A Systematic Literature Review and Case Report

  2022cites this paper
• The Study of the Nanocrystalline Structure of Psammoma Bodies of Serous Ovarian Carcinoma

  2022cites this paper
• An Application of Machine Learning That Uses the Magnetic Resonance Imaging Metric, Mean Apparent Diffusion Coefficient, to Differentiate between the Histological Types of Ovarian Cancer

  2021cites this paper
• Potential Role of Hydroxyapatite Nanocrystalline for Early Diagnostics of Ovarian Cancer

  2021cites this paper
• Apparent diffusion coefficient (ADC) values of serous, endometrioid, and clear cell carcinoma of the ovary: pathological correlation

  2019cites this paper
• A COEUR cohort study of SATB2 expression and its prognostic value in ovarian endometrioid carcinoma

  2019cites this paper
• Low Grade Ovarian Serous Carcinoma - A Clinical-Morphologic Study

  2019influential citation
• Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers

  2018cites this paper
• Architectural Histopathological Changes in Ovarian Serous Carcinomas

  2018influential citation
• Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging.

  2017cites this paper
• Expression of Carbonic Anhydrases II, IX and XII in the Normal Female Reproductive Tract, Gynecological Tumors and Lynch Syndrome

  2014cites this paper